Disc Medicine (IRON) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Disc Medicine (IRON) over the past year, gaining 483.4% versus a loss of 13.5%. Over five years, SLS leads with a +27.5% price change compared with -45.5% for IRON. Disc Medicine is the larger company by market cap ($2.33 billion vs $2.27 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | SLS |
|---|---|---|
| Share price | $60.77 | $11.26 |
| Market cap | $2.33B | $2.27B |
| 1-day change | -0.67% | -0.44% |
| YTD return | -23.47% | +198.67% |
| 1-year return | -13.53% | +483.42% |
| 5-year return | -45.55% | +27.52% |
| EPS (TTM) | $-6.58 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $99.50 | $15.88 |
| 52-week low | $40.00 | $1.39 |
| Distance from 52-week high | -38.92% | -29.09% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +69.77% | +188.63% |
| Average volume | 471.18K | 6.52M |
| Shares outstanding | 38.39M | 201.95M |
| Employees | 165 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed IRON by 497.0 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
IRON vs SLS FAQ
Which is bigger, Disc Medicine or SELLAS Life Sciences Group?
Disc Medicine (IRON) is larger, with a market capitalization of $2.33B compared with $2.27B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, IRON or SLS?
SLS returned +483.42% over the past 12 months, compared with -13.53% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.